Clinical Characteristics of Multiple Sclerosis in Kuwait: Data From the New MS Registry of Amiri Hospital

REFERENCES

• Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg. 2002 Jul;104(3):182-91.
   Google Scholar
• Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci. 2001 Apr;22(2):117-39.
   Google Scholar
• Sellner J, Kraus J, Awad A, Milo R, Hemmer B, Stuve O. The increasing incidence and prevalence of female multiple sclerosis—a critical analysis of potential environmental factors. Autoimmun Rev. 2011;10:495-502.
   PubMed Web of Science ®Google Scholar
• Bronnum-Hansen H, Koch-Henriksen N, Hyllested K. Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology. 1994 Oct;44(10):1901-7.
   Google Scholar
• Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry. 1992 Aug;55(8):671-6.
   Google Scholar
• Culpepper WJ 2nd, Ehrmantraut M, Wallin MT, Flannery K, Bradham DD. Veterans Health Administration multiple sclerosis surveillance registry: the problem of case-finding from administrative databases. J Rehabil Res Dev. 2006 Jan-Feb;43(1):17-24.
   Google Scholar
• Studney DR, Lubin FD, Marcucci L. MS COSTAR: A PC based medical information system to support and pool data among multiple sclerosis clinics. Proc Annu Symp Comput Appl Med Care J. 1989;8:943-4.
   Google Scholar
• Hurwitz BJ. Registry studies of long-term multiple sclerosis outcomes: description of key registries. Neurology. 2011 Jan 4;76(1 Suppl 1):S3-6.
   Google Scholar
• Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: diagnosis. Mult Scler. 2007 Jul;13(6):770-5.
   Google Scholar
• Al-Hashel J, Besterman AD, Wolfson C. The prevalence of multiple sclerosis in the Middle East. Neuroepidemiology. 2008;31(2):129-37.
   Google Scholar
• Alshubaili AF, Alramzy K, Ayyad YM, Gerish Y. Epidemiology of multiple sclerosis in Kuwait: new trends in incidence and prevalence. Eur Neurol. 2005;53(3):125-31.
   Google Scholar
• Alter M, Kahana E, Zilber N, Miller A. Multiple sclerosis frequency in Israel's diverse populations. Neurology. 2006 Apr 11;66(7):1061-6.
   Google Scholar
• Benamer HT, Ahmed ES, Al-Din AS, Grosset DG. Frequency and clinical patterns of multiple sclerosis in Arab countries: a systematic review. J Neurol Sci. 2009 Mar 15;278(1-2):1-4.
   Google Scholar
• El-Salem K, Al-Shimmery E, Horany K, Al-Refai A, Al-Hayk K, Khader Y. Multiple sclerosis in Jordan: a clinical and epidemiological study. J Neurol. 2006 Sep;253(9):1210-6.
   Google Scholar
• Maghzi AH, Ghazavi H, Ahsan M, Etemadifar M, Mousavi S, Khorvash F, Minagar A. Increasing female preponderance of multiple sclerosis in Isfahan, Iran: a population-based study. Mult Scler. 2010 Mar;16(3):359-61.
   Google Scholar
• Yamout B, Itani S, Arabi A, Hamzeh D, Yaghi S. Prognostic factors of multiple sclerosis in Lebanon. Int J Neurosci. 2010 Mar;120(3):206-10.
   Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52.
   Google Scholar
• Abstracts of the World Congress on Treatment and Research in Multiple Sclerosis, September 17-20, 2008, Montreal, Canada. Mult Scler. 2008 Sep;14 Suppl 1:S1-314.
   Google Scholar
• Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9.
   Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology. 1996 Apr;46(4):907-11.
   Google Scholar
• Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005 Dec;58(6):840-6.
   Google Scholar
• Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005 May;4(5):281-8.
   Google Scholar
• Pestalozza IF, Pozzilli C, Di Legge S, Piattella MC, Pantano P, Caramia F, Pasqualetti P, Lenzi GL. Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome. Mult Scler. 2005 Aug;11(4):390-4.
   Google Scholar
• Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, Huerga E, Miszkiel KA, Plant GT, Polman C, Rovaris M, Thompson AJ, Montalban X, Miller DH. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 2007 Aug;6(8):677-86.
   Google Scholar
• Thrower BW. Clinically isolated syndromes: predicting and delaying multiple sclerosis. Neurology. 2007 Jun 12;68(24 Suppl 4):S12-5.
   Google Scholar
• Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2006 Jan 24;66(2):172-7.
   Google Scholar
• Ferreira ML, Machado MI, Dantas MJ, Moreira AJ, Souza AM. Pediatric multiple sclerosis: analysis of clinical and epidemiological aspects according to National MS Society Consensus 2007. Arq Neuropsiquiatr. 2008 Sep;66(3B):665-70.
   Google Scholar
• Chitnis T, Krupp L, Yeh A, Rubin J, Kuntz N, Strober JB, Chabas D, Weinstock-Guttmann B, Ness J, Rodriguez M, Waubant E. Pediatric multiple sclerosis. Neurol Clin. 2011 May;29(2):481-505.
   Google Scholar
• Liu C, Blumhardt LD. Disability outcome measures in therapeutic trials of relapsing–remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):450-7.
   Google Scholar
• Trojano M, Paolicelli D, Tortorella C, Iaffaldano P, Lucchese G, Di Renzo V, D'Onghia M. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? Neurol Clin. 2011 May;29(2):309-21.
   Google Scholar
• Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3): 227-31.
   Google Scholar
• Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasasainagendra V, Cutter GR. Assessing changes in relapse rates in multiple sclerosis. Mult Scler. 2010 Dec;16(12):1414-21.
   Google Scholar
• Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):416-26.
   Google Scholar
• Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 Feb 4;362(5):387-401.
   Google Scholar
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):655-61.
   Google Scholar
• Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998 Nov 7;352(9139):1498-504.
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996 Mar;39(3):285-94.
   Google Scholar
• Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008 Feb;255(2):280-7.
   Google Scholar
• Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):148-52.
   Google Scholar
• Pittock SJ, McClelland RL, Mayr WT, Jorgensen NW, Weinshenker BG, Noseworthy J, Rodriguez M. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol. 2004 Aug;56(2):303-6.
   Google Scholar
• Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of “benign” multiple sclerosis at 20 years. Neurology. 2007 Feb 13;68(7):496-500.
   Google Scholar
• Thompson AJ, Hutchinson M, Brazil J, Feighery C, Martin EA. A clinical and laboratory study of benign multiple sclerosis. Q J Med. 1986 Jan;58(225):69-80.
   Google Scholar
• Inshasi J, Thakre M. Prevalence of multiple sclerosis in Dubai, United Arab Emirates. Int J Neurosci. 2011;121:393-8.
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Zettl UK, Gotze U, Haas J, Schimrigk S, Elias W, Pette M, Eulitz M, Hennig M, Bertram J, Hollweck R, Neiss A, Daumer M, Pitschnau-Michel D, Rieckmann P. MS registry in Germany—design and first results of the pilot phase. Nervenarzt. 2005 Aug;76(8):967-75.
   Google Scholar
• Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003 Apr;126(Pt 4):770-82.
   Google Scholar
• Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol. 2008 Sep;15(9):916-21.
   Google Scholar
• Riise T, Gronning M, Fernandez O, Lauer K, Midgard R, Minderhoud JM, Nyland H, Palffy G, Poser S, Aarli JA. Early prognostic factors for disability in multiple sclerosis, a European multicenter study. Acta Neurol Scand. 1992 Mar;85(3):212-8.
   Google Scholar
• Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci. 2003 Feb 15;206(2):165-71.
   Google Scholar
• Al-Araji A, Mohammed AI. Multiple sclerosis in Iraq: does it have the same features encountered in Western countries? J Neurol Sci. 2005 Jul 15;234(1–2):67-71.
   Google Scholar
• Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J, Pakdaman H. Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. Eur Neurol. 2010;64(6):331-6.
   Google Scholar
• Turk Boru U, Alp R, Sur H, Gul L. Prevalence of multiple sclerosis door-to-door survey in Maltepe, Istanbul, Turkey. Neuroepidemiology. 2006;27(1):17-21.
   Google Scholar